查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972085

抗菌藥物抗藥性診斷市場：按技術、產品類型、測試類型、檢體類型、病原體、應用和最終用戶分類－2026年至2032年全球預測

Antimicrobial Resistance Diagnostic Market by Technology, Product, Test Type, Sample Type, Pathogen, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗菌藥物抗藥性診斷市場價值將達到 50.7 億美元，到 2026 年將成長至 54 億美元，到 2032 年將達到 79.8 億美元，複合年成長率為 6.69%。

主要市場統計數據
基準年 2025 50.7億美元
預計年份：2026年 54億美元
預測年份 2032 79.8億美元
複合年成長率 (%) 6.69%

這是一份簡明扼要的抗生素抗藥性診斷策略指南。它提出了一個框架，用於分析影響近期決策的不斷變化的臨床、技術和製度因素。

抗菌素抗藥性（AMR）已從公共衛生問題演變為醫療保健系統、診斷公司和生命科學機構面臨的策略挑戰。能夠檢測抗藥性機制並指導合理治療的診斷平台已成為臨床決策、合理使用抗菌藥物方案和藥物開發平臺的核心。隨著檢測網路的現代化以及臨床醫生對快速、可操作結果的需求，診斷領域正朝著結合分子精準性、表現型背景和強巨量資料分析能力的整合解決方案方向發展。

診斷技術的融合、定序技術的進步以及以服務為導向的商業模式的重大變革，正在重新定義臨床和商業性的優先事項。

在抗菌藥物抗藥性（AMR）診斷領域，正在發生多項變革性變化，這些變化正在重新定義產品開發的重點和市場進入策略。首先，診斷領域正朝著「診斷融合」的方向發展，即基因組分析方法（例如次世代定序）與快速分子檢測和質譜分析相結合。這種融合模式兼顧了全基因組或靶向定序的全面概覽、基於PCR的檢測方法的速度和臨床效用以及質譜分析的表現型解析度，使臨床醫生能夠在臨床可接受的時限內獲得鑑定和抗藥性標記數據。

對 2025 年關稅措施將如何促進整個診斷價值鏈的供應鏈多元化、採購條款重新談判和製造地重組進行實際評估。

美國將於2025年實施新的關稅措施和貿易政策調整，將進一步增加抗菌藥物抗藥性（AMR）診斷供應鏈中製造商、經銷商和臨床實驗室的營運複雜性。關稅帶來的成本壓力正對設備採購、試劑採購和耗材補充產生連鎖反應，迫使各機構重新評估籌資策略、供應商多元化和庫存管理方法。在許多情況下，採購團隊需要在短期成本增加和長期營運韌性之間尋求平衡。

透過對技術、產品、測試類型、最終用戶、應用、檢體類型和病原體領域進行詳細的細分分析，我們制定有針對性的產品和市場策略。

市場區隔的詳細分析揭示了臨床需求、技術可行性和商業性機會的交匯點。目前正在研究的技術包括質譜、微陣列平台、次世代定序和聚合酵素鏈鎖反應(PCR)。在次世代定序領域，長讀長定序和短讀長定定序的互補優勢在闡明抗藥性決定因素和建立監測系統方面備受重視。從產品角度來看，市場包括儀器、試劑和耗材，以及不斷成長的軟體和服務層。軟體和服務領域進一步細分為諮詢和支援服務，旨在幫助使用者實現複雜的工作流程。

影響招聘管道、監管要求和商業性策略的區域趨勢（美洲和南美洲、歐洲、中東和非洲以及亞太市場）

區域趨勢顯著影響抗菌藥物抗藥性（AMR）診斷領域的應用曲線、調節路徑和商業模式。在美洲，先進的檢查室基礎設施、一體化的醫院網路和健全的公共衛生監測計畫推動了對高通量標準解決方案和快速分子檢測的需求。區域報銷框架和機構採購行為往往強調已驗證的臨床效用以及與合理抗菌藥物使用目標的明確關聯，這可能有利於那些能夠檢驗對患者療效產生可衡量影響的供應商。

在競爭與合作並存的企業間動態中，成熟企業的規模與敏捷的創新者攜手合作，推動技術應用與服務主導的差異化。

在先進醫療診斷領域，競爭格局呈現既有成熟的生命科學集團，也小規模、專注於創新的創新企業並存的局面。現有的診斷設備製造商利用涵蓋設備、耗材和整合資訊系統的廣泛產品組合，提供端到端的解決方案，以最佳化工作流程並滿足法規遵循要求。這些大型公司通常會在全球服務網路、品管系統和上市後監測能力方面投入大量資金，以確保醫院系統和標準實驗室能夠滿足其對連續性和擴充性的需求。

促進推廣應用的實用建議：產品模組化、可互通的分析技術、強大的供應鏈和基於證據的商業化。

產業領導者應採取平衡策略，將技術創新與切實可行的商業性執行相結合，以掌握抗菌藥物抗藥性（AMR）診斷領域的機會。首先，他們應優先考慮模組化產品架構，以實現跨平台試劑標準化，並簡化跨多個司法管轄區的監管申報流程。此類設計可降低客戶的整體擁有成本，並增強製造商應對區域採購和關稅壓力的柔軟性。其次，他們應投資於可互通的軟體和分析技術，將基因組和分子層面的分析結果轉化為簡潔明了的臨床見解。這可減輕檢查室和臨床人員的認知負擔，並加快決策速度。

本報告的研究採用了穩健的多方法研究設計，結合了對主要相關人員的訪談、二手證據的整合、資料三角測量和情境分析，以確保方法的嚴謹性和相關性。

本報告的研究整合了多個資料收集和檢驗層級，以確保調查方法的嚴謹性和相關性。主要研究包括對臨床實驗室主任、採購經理、診斷產品經理和公共衛生官員進行結構化訪談，以收集關於技術採納、採購限制和營運重點的第一手觀點。此外，還與服務供應商和技術專家進行了對話，以了解不同檢測環境中的挑戰和支援需求。

對決定不斷發展的 AMR 診斷環境成功的技術要求、供應鏈實際情況和策略重點進行綜合分析。

總之，抗菌藥物抗藥性診斷領域已進入關鍵階段，技術能力、服務整合和供應鏈韌性正在決定競爭優勢。先進的定序、快速分子檢測和質譜分析各自發揮互補作用，而軟體和諮詢服務對於將複雜的檢測結果轉化為臨床適用的建議也變得日益重要。監管現代化、抗菌藥物管理要求和採購趨勢正在影響醫院、參考實驗室和研究機構的採納路徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗菌素抗藥性診斷市場：依技術分類

  • 質譜分析
  • 微陣列
  • 次世代定序
    • 長讀長定定序
    • 短讀定序
  • 聚合酵素鏈鎖反應（PCR）

第9章：抗菌素抗藥性診斷市場：依產品分類

  • 裝置
  • 試劑和耗材
  • 軟體和服務
    • 服務
      • 諮詢服務
      • 支援服務
    • 軟體

第10章：按檢測類型分類的抗菌素抗藥性診斷市場

  • 基因分型
    • 標靶檢測
    • 全基因測序
  • 表現型檢測

第11章：按檢體類型分類的抗菌素抗藥性診斷市場

  • 血液檢體
  • 呼吸道檢體
  • 尿液檢體
  • 傷口拭子

第12章：按病原體分類的抗菌素抗藥性診斷市場

  • 真菌
  • 革蘭氏陰性菌
  • 革蘭氏陽性菌

第13章：抗菌素抗藥性診斷市場：依應用分類

  • 人類診斷
  • 藥品和生物製藥
  • 獸醫診斷

第14章：抗菌素抗藥性診斷市場：依最終用戶分類

  • 學術和研究機構
  • 診斷中心
  • 醫院和診所
  • 參考測試機構

第15章：抗菌素抗藥性診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：抗菌藥物抗藥性診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 抗菌藥物抗藥性診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國抗菌素抗藥性診斷市場

第19章：中國抗菌藥物抗藥性診斷市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • QIAGEN NV
  • Roche Diagnostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Vela Diagnostics
Product Code: MRR-2B5802CFEB38

The Antimicrobial Resistance Diagnostic Market was valued at USD 5.07 billion in 2025 and is projected to grow to USD 5.40 billion in 2026, with a CAGR of 6.69%, reaching USD 7.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.07 billion
Estimated Year [2026] USD 5.40 billion
Forecast Year [2032] USD 7.98 billion
CAGR (%) 6.69%

A concise strategic orientation to antimicrobial resistance diagnostics that frames the evolving clinical, technological, and institutional drivers shaping near-term decision-making

Antimicrobial resistance (AMR) has intensified from a public health concern into a strategic challenge for healthcare systems, diagnostics companies, and life sciences organizations. Diagnostic platforms that detect resistance mechanisms and guide appropriate therapy are now central to clinical decision-making, antimicrobial stewardship programs, and drug development pipelines. As laboratory networks modernize and clinicians demand faster, more actionable results, the diagnostic landscape is shifting toward integrated solutions that combine molecular precision, phenotypic context, and robust data analytics.

The convergence of advanced sequencing, rapid polymerase chain reaction (PCR) assays, mass spectrometry, and bioinformatic services has elevated the role of diagnostics from a confirmatory tool to a predictive instrument that shapes clinical pathways. Meanwhile, institutional imperatives-such as reducing hospital-acquired infections, improving antimicrobial use, and meeting regulatory reporting requirements-are re-prioritizing investments across hospitals, reference laboratories, and academic centers. These forces are being amplified by increasing cross-sector collaboration among diagnostic developers, pharmaceutical manufacturers, and governmental public health entities.

Against this backdrop, strategic leaders must assess not only the technical performance of diagnostic modalities but also how procurement, supply chains, regulatory frameworks, and payer dynamics influence adoption. The following sections unpack transformative shifts, regulatory and trade impacts, segmentation-level insights, regional opportunities and constraints, competitive dynamics, and pragmatic recommendations for organizations navigating the AMR diagnostics environment.

Critical transformative shifts in diagnostic convergence, sequencing advances, and service-oriented commercial models that are redefining clinical and commercial priorities

The landscape for AMR diagnostics is undergoing several transformative shifts that together redefine product development priorities and market access strategies. First, there is a clear movement toward diagnostic convergence where genomic approaches such as next generation sequencing are complemented by rapid molecular testing and mass spectrometry. This blended model balances the comprehensive overview afforded by whole genome or targeted sequencing with the speed and clinical utility of PCR-based assays and the phenotypic resolution of mass spectrometry, enabling clinicians to obtain both identification and resistance marker data within clinically relevant timelines.

Second, the maturation of long read sequencing technologies alongside short read approaches is unlocking new capabilities for resolving complex resistance loci, plasmids, and structural variants that were previously opaque to routine testing. As informatics pipelines and databases improve, genomic outputs are becoming more actionable, supporting outbreak detection, transmission mapping, and refined susceptibility predictions. Third, the role of software and services is expanding from backend analytics to front-line decision support; consultancy and support services are increasingly bundled with instruments and consumables to accelerate adoption and demonstrate return on investment to end users.

Fourth, the rise of decentralized testing models-driven by diagnostic centers and point-of-care initiatives-demands robust, easy-to-use systems and streamlined reagent supply chains. Finally, macro-level forces such as regulatory modernization, public-private stewardship initiatives, and funding directed at surveillance infrastructure are realigning incentives. Collectively, these shifts are creating an environment in which integrated, interoperable diagnostics offerings that deliver speed, accuracy, and actionable interpretation will command competitive advantage.

A pragmatic assessment of how 2025 tariff measures are catalyzing supply chain diversification, procurement renegotiation, and manufacturing realignment across diagnostic value chains

The introduction of new tariff measures and trade policy adjustments in the United States in 2025 has introduced an additional layer of complexity for manufacturers, distributors, and clinical laboratories engaged in the AMR diagnostics supply chain. Tariff-induced cost pressures have ripple effects across instrument procurement, reagent sourcing, and consumables replenishment, prompting organizations to reassess sourcing strategies, supplier diversification, and inventory management practices. In many cases, procurement teams are balancing the trade-offs between short-term cost increases and long-term operational resilience.

These trade-related frictions are accelerating supply chain strategies that prioritize geographic diversification and local manufacturing capability. Some manufacturers are evaluating onshoring or nearshoring of critical reagent production to reduce exposure to tariff volatility and shipping disruptions. Others are renegotiating distributor agreements to insulate downstream customers from price spikes while preserving service continuity. For clinical laboratories and health systems, the immediate operational response often includes renegotiated contracting terms, longer-term supply agreements, and targeted inventory buffering for high-use reagent lines.

In parallel, there is an observable shift in vendor selection criteria where total cost of ownership, supplier risk metrics, and lifecycle service commitments gain prominence. For product developers, tariff pressures underscore the importance of modular instrument designs, reagent standardization across platforms, and ecosystem partnerships that can smooth cross-border supply constraints. Overall, the 2025 tariff environment has acted as a catalyst for structural supply chain changes and strategic re-prioritization across the diagnostics value chain.

In-depth segmentation insights across technology, product, test type, end-user, application, sample type, and pathogen domains to guide targeted product and market strategies

A granular view of market segmentation illuminates where clinical demand, technological capability, and commercial opportunity intersect. Technologies under active study include mass spectrometry, microarray platforms, next generation sequencing, and polymerase chain reaction; within next generation sequencing, both long read sequencing and short read sequencing are being evaluated for their complementary strengths in resolving resistance determinants and enabling surveillance. From a product standpoint, the market comprises instruments, reagents and consumables, and an expanding layer of software and services; the software and services domain further breaks down into consulting services and support services that help institutions operationalize complex workflows.

Test-type distinctions continue to matter for adoption patterns. Genotypic tests, which include targeted assays and whole genome sequencing, provide molecular-level insights and are increasingly used for resistance mechanism detection and epidemiologic tracing, while phenotypic tests remain essential for confirming susceptibility and guiding immediate therapeutic decisions. End users range from academic and research institutions to diagnostic centers, hospitals and clinics, and reference laboratories; each category has distinct purchasing cycles, validation requirements, and throughput expectations that influence product design and commercial outreach.

Applications span human diagnostics, pharmaceutical and biopharmaceutical research, and veterinary diagnostics, reflecting the One Health perspective that links human, animal, and environmental resistance dynamics. Sample types in routine workflows include blood samples, respiratory samples, urine samples, and wound swabs, with each specimen class imposing unique pre-analytical and analytical constraints. Pathogen focus covers fungi, gram negative bacteria, and gram positive bacteria, each presenting different resistance mechanisms and diagnostic sensitivity challenges. Together, these segmentation dimensions provide a roadmap for tailoring product features, regulatory strategies, and commercialization tactics to meet heterogeneous clinical and research needs.

Regional dynamics that influence adoption pathways, regulatory requirements, and commercial approaches across Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics significantly shape adoption curves, regulatory pathways, and commercial models in the AMR diagnostics space. In the Americas, advanced laboratory infrastructure, integrated hospital networks, and strong public health surveillance programs create demand for both high-throughput reference solutions and rapid molecular tests. Reimbursement frameworks and institutional purchasing behaviors in this region often favor validated clinical utility and clear linkage to antimicrobial stewardship goals, which can favor suppliers able to demonstrate measurable impact on patient outcomes.

In Europe, Middle East & Africa, variability in healthcare funding, laboratory capacity, and regulatory environments creates a diverse set of entry strategies. High-income European markets prioritize conformity to stringent regulatory and quality standards and often require local validation and interoperability with electronic health records. In several countries across the broader region, public health initiatives and donor-funded programs are driving investment in surveillance and laboratory strengthening, opening opportunities for scalable, ruggedized systems suitable for decentralized settings.

The Asia-Pacific region exhibits a combination of rapid adoption in urban centers, significant investment in genomic and molecular capabilities, and a large base of clinical laboratories with variable resource profiles. Manufacturers targeting this region benefit from flexible product configurations that accommodate both high-throughput centralized labs and decentralized diagnostic centers. Across all regions, partnerships with local distributors, attention to regulatory timelines, and sensitivity to procurement cycles are critical determinants of commercial success.

Competitive and collaborative company dynamics showing how incumbent scale and nimble innovators together drive technological adoption and service-led differentiation

Competitive dynamics in the AMR diagnostics arena are characterized by a mix of established life science conglomerates and smaller specialized innovators. Incumbent diagnostics manufacturers leverage broad portfolios that span instruments, consumables, and integrated informatics to offer end-to-end solutions for workflow efficiency and regulatory compliance. These larger firms typically invest heavily in global service networks, quality systems, and post-market surveillance capabilities that reassure hospital systems and reference laboratories seeking continuity and scalability.

At the same time, agile technology companies and start-ups are driving innovation through focused advances in sequencing chemistry, rapid PCR assays, and interpretation software. Their strengths lie in rapid iteration, niche clinical validation studies, and partnerships with academic centers that accelerate clinical evidence generation. Collaboration between incumbents and innovators is increasingly common, enabling the scaling of novel assays while benefiting from established distribution and regulatory expertise.

Strategic alliances with pharmaceutical and biopharmaceutical firms are also prominent, as companion diagnostics and resistance profiling become integral to drug development and clinical trials. Moreover, an emerging services ecosystem-including consulting and support offerings-helps institutions implement complex workflows and extract value from rich genomic and phenotypic data. For stakeholders, competitive positioning now depends on the ability to combine technological differentiation with demonstrable clinical utility and robust service commitments.

Actionable and pragmatic recommendations for product modularity, interoperable analytics, resilient supply chains, and evidence-driven commercialization to accelerate adoption

Industry leaders should pursue a balanced strategy that aligns technological innovation with pragmatic commercial execution to capture opportunities in AMR diagnostics. First, prioritize modular product architectures that enable cross-platform reagent standardization and simplify regulatory submissions across multiple jurisdictions. Such designs reduce total cost of ownership for customers and increase flexibility for manufacturers to adapt to regional procurement and tariff pressures. Second, invest in interoperable software and analytics that translate genomic and molecular outputs into concise clinical intelligence, thereby reducing the cognitive load on laboratory and clinical staff and accelerating decision-making.

Third, develop strategic supply chain programs that combine localized manufacturing or co-manufacturing arrangements with diversified distributor networks to mitigate trade-related disruptions and tariff exposure. Fourth, adopt an evidence-first commercialization approach that pairs pragmatic clinical studies with real-world performance data; demonstrating impact on antimicrobial stewardship metrics, turnaround times, and treatment pathways will be critical to secure institutional buy-in. Fifth, cultivate partnerships across the One Health spectrum, engaging veterinary diagnostics, pharmaceutical partners, and public health agencies to broaden surveillance coverage and create multi-sector value propositions.

Finally, strengthen customer enablement through consulting and support services that address laboratory workflow optimization, staff training, and data governance. This service-led approach not only accelerates adoption but creates recurring revenue pathways and deeper client relationships. Collectively, these steps position leaders to navigate regulatory complexities, tariff shocks, and rapidly evolving clinical expectations while delivering solutions that materially improve resistance detection and patient care.

A robust multi-method research design combining primary stakeholder interviews, secondary evidence synthesis, data triangulation, and scenario analysis to ensure rigor

The research underpinning this report integrates multiple data collection and validation layers to ensure methodological rigor and relevance. Primary research comprised structured interviews with clinical laboratory directors, procurement leads, diagnostic product managers, and public health officials to capture first-hand perspectives on technology adoption, procurement constraints, and operational priorities. These interviews were supplemented by engagements with service providers and technical specialists to understand implementation challenges and support requirements across diverse laboratory settings.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, public health surveillance reports, and technology white papers to contextualize primary findings and trace the evolution of assay performance characteristics. Where applicable, technical specifications and regulatory filings were examined to validate claims regarding platform capabilities and intended use. Data triangulation was used to cross-check interview inputs with documented evidence and to surface consistent themes across stakeholder groups.

Analytical approaches included segmentation mapping to align technology capabilities with end-user needs, scenario analysis to assess the operational impacts of policy and tariff shifts, and sensitivity testing to identify key commercial levers. Quality control protocols encompassed respondent verification, documentation of data sources, and iterative review cycles with subject matter experts to refine interpretations. Together, this methodology provides a transparent and defensible foundation for the insights and recommendations presented in the report.

Concluding synthesis of technological imperatives, supply chain realities, and strategic priorities that determine success in the evolving AMR diagnostics landscape

In sum, the diagnostics landscape for antimicrobial resistance is entering a phase where technological capability, service integration, and supply chain resilience determine competitive advantage. Advanced sequencing, rapid molecular assays, and mass spectrometry are each playing complementary roles, while software and consulting services are increasingly essential to convert complex outputs into clinically actionable recommendations. Regulatory modernization, stewardship imperatives, and procurement dynamics are shaping adoption pathways across hospitals, reference labs, and research institutions.

Trade policy shifts and tariff measures in 2025 have highlighted vulnerabilities in global reagent and consumable supply chains, prompting manufacturers and buyers to re-evaluate sourcing strategies and invest in mitigations such as localized manufacturing and diversified distribution agreements. Region-specific dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific will require tailored approaches that reflect differing regulatory regimes, laboratory capacities, and funding mechanisms. The most successful players will combine technological differentiation with demonstrable clinical utility and robust service commitments to support implementation and scale.

Ultimately, stakeholders that act decisively-prioritizing interoperable designs, evidence generation, and resilient commercial models-will be best positioned to meet the evolving needs of clinicians and public health systems while contributing to more effective detection and management of antimicrobial resistance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Resistance Diagnostic Market, by Technology

  • 8.1. Mass Spectrometry
  • 8.2. Microarray
  • 8.3. Next Generation Sequencing
    • 8.3.1. Long Read Sequencing
    • 8.3.2. Short Read Sequencing
  • 8.4. Polymerase Chain Reaction (PCR)

9. Antimicrobial Resistance Diagnostic Market, by Product

  • 9.1. Instruments
  • 9.2. Reagents & Consumables
  • 9.3. Software & Services
    • 9.3.1. Services
      • 9.3.1.1. Consulting Services
      • 9.3.1.2. Support Services
    • 9.3.2. Software

10. Antimicrobial Resistance Diagnostic Market, by Test Type

  • 10.1. Genotypic Tests
    • 10.1.1. Targeted Assays
    • 10.1.2. Whole Genome Sequencing
  • 10.2. Phenotypic Tests

11. Antimicrobial Resistance Diagnostic Market, by Sample Type

  • 11.1. Blood Samples
  • 11.2. Respiratory Samples
  • 11.3. Urine Samples
  • 11.4. Wound Swabs

12. Antimicrobial Resistance Diagnostic Market, by Pathogen

  • 12.1. Fungi
  • 12.2. Gram Negative Bacteria
  • 12.3. Gram Positive Bacteria

13. Antimicrobial Resistance Diagnostic Market, by Application

  • 13.1. Human Diagnostics
  • 13.2. Pharmaceutical & Biopharmaceutical
  • 13.3. Veterinary Diagnostics

14. Antimicrobial Resistance Diagnostic Market, by End User

  • 14.1. Academic & Research Institutions
  • 14.2. Diagnostic Centers
  • 14.3. Hospitals & Clinics
  • 14.4. Reference Laboratories

15. Antimicrobial Resistance Diagnostic Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Antimicrobial Resistance Diagnostic Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Antimicrobial Resistance Diagnostic Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Antimicrobial Resistance Diagnostic Market

19. China Antimicrobial Resistance Diagnostic Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Becton, Dickinson and Company
  • 20.7. Bio-Rad Laboratories, Inc.
  • 20.8. bioMerieux SA
  • 20.9. Bruker Corporation
  • 20.10. Danaher Corporation
  • 20.11. QIAGEN N.V.
  • 20.12. Roche Diagnostics
  • 20.13. Siemens Healthineers AG
  • 20.14. Thermo Fisher Scientific Inc.
  • 20.15. Vela Diagnostics

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LONG READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LONG READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LONG READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SHORT READ SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SHORT READ SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SHORT READ SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TARGETED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TARGETED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TARGETED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHENOTYPIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHENOTYPIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHENOTYPIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESPIRATORY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESPIRATORY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESPIRATORY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY URINE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY URINE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WOUND SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY WOUND SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HUMAN DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HUMAN DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HUMAN DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY GENOTYPIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2